Cencora, Inc. COR reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over ...

The firm's lead program, MET-097i, is in Phase 2b trial as a 'fully biased GLP ... equivalents to fund the completion of the Phase 2 clinical trials for MET-097i, to advance MET-233i through Phase ...

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Ocean demand being pulled forward. The main debate regarding the container ship market is whether several factors will converge to tank rates later this year. Most industry profes ...

Q1 2025 Earnings Call Transcript February 10, 2025 Rockwell Automation, Inc. beats earnings expectations. Reported EPS is ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

Share on Pinterest Women with diabetes may get the strongest cardiovascular protection from GLP-1 agonists. Image credit: Kathryn Gamble for The Washington Post via Getty Images. Diabetes ...

If you continue to have this issue please contact [email protected]. Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

But virtual diabetes and weight management care changed when GLP-1 drug Wegovy was approved for weight loss in June 2021. As the drugs' popularity reached new heights, it became an expensive item ...

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...